SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after the National Comprehensive Cancer Network updated its clinical guidelines to include ANKTIVA plus BCG for patients with BCG-unresponsive papillary-only bladder cancer. The community is actively discussing this update as a major catalyst that enables immediate insurance reimbursement and expanded physician adoption, effectively bypassing wait times for formal FDA label expansion.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently a major focus for investors navigating high volatility as they weigh the company's long-term nuclear energy ambitions against immediate regulatory and financial pressures. The community remains deeply polarized, with bulls pointing to strategic partnerships and potential government-backed clean energy catalysts, while bears express significant skepticism regarding the firm's pre-revenue status, insider selling, and extended development timelines.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending after reporting that the non-HLA-A*02 arm of its Phase III FLAMINGO-01 trial shows a continued reduction in recurrence rates, mirroring promising Phase II results. The community is actively discussing the potential for a major data catalyst following the announcement that the full Steering Committee will co-author upcoming AACR abstracts, with many longs viewing recent price consolidation as a strategic entry point.

Aventus Network

Aventus Network is currently trending as community members discuss its potential for a breakout, fueled by its enterprise-grade technology, Polkadot integration, and the recent incorporation of its DAO in the UAE. Investors are actively highlighting the project's low market capitalization and strategic advisory appointments as bullish catalysts while keeping a close watch on trading volume for signs of sustained momentum.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings Inc. is trending as investors digest news of multiple strategic forward-flow agreements and a national bank charter application, despite persistent volatility and concerns about the stock's performance compared to broader fintech peers. The community remains deeply divided, with some traders actively looking for a short squeeze fueled by significant short interest, while others express frustration over the stock's inability to hold gains.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging after securing a massive five-year, $27 billion AI infrastructure deal with Meta, which further validates the company's status as a key hyperscaler in the high-performance compute market. Investors and the community are aggressively bullish, citing the combination of this new contract, significant recent backing from Nvidia, and the company's strategic positioning to dominate physical AI and robotics compute as catalysts for long-term growth.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is trending as investors weigh strong top-line demand against ongoing operational challenges, including industry-wide flight disruptions, rising fuel costs, and labor-management tensions. The community remains divided, with some traders betting on a turnaround fueled by historical booking strength and technical signals, while others express deep skepticism regarding the company's high debt load and underperformance relative to airline peers.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors focus on the recent appointment of Ted Warner as CFO, which the community interprets as a signal of imminent hyperscaler partnerships. While some traders are capitalizing on high volatility and speculative momentum, others are voicing frustration over delayed tenant announcements and potential dilution, maintaining a cautious wait-and-see approach.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is currently in the spotlight as investors digest mixed quarterly earnings that showcased a strong premium travel business but highlighted lingering concerns regarding high labor costs and cautious forward guidance. The community is actively debating the company's long-term resilience, weighing the positive momentum of its international fleet expansion against near-term operational headwinds.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively position themselves ahead of the upcoming earnings report, driven by analyst price target hikes and bullish sentiment surrounding its critical role in AI memory infrastructure. The community is heavily focused on the company's high-volume HBM4 production for NVIDIA's Vera Rubin systems and the broader memory super-cycle, with intense debate ongoing between bulls anticipating a breakout toward new highs and bears wary of overvaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average - Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Below 50-Day Moving Average - Here's Why...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 21,087...

Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...

<ul class="summary-bullets"><li>With Abivax now trading as a strategic asset rather than a pure clinical story, takeover interest from a deep-pocketed pharma player introduces a potential valuation floor.</li><li>At roughly an $11 billion market cap, the stock is priced with strong odds of UC success and meaningful commercialization.</li><li>There is still room for upside if Crohn’s disease data validate a broader, multi-indication franchise.</li></ul>French clinical-stage biotech Abivax (ABVX) had an uneventful Nasdaq debut in October 2023 and spent much of its early public life flying under the radar. That changed abruptly this year after a single clinical data readout flipped the narrative — a familiar inflection point in biotech investing.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax’s stock</a> is up nearly 1,900% year-to-date, making it the best-performing biotech stock&nbsp;on U.S. exchanges.Adding fuel to the mid-year momentum, Eli Lilly (LLY) has emerged as a potential suitor, with market chatter suggesting the pharma giant is circling the smaller biotech. French media outlet La Lettre reported earlier this week that a delegation of Lilly executives met with the French Treasury and&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2025/12/22/l-americain-eli-lilly-en-operation-seduction-a-bercy-pour-racheter-la-biotech-abivax,110583257-art">submitted</a> an acquisition proposal for Abivax.How does this shift the investment thesis around this smaller name? What was once a high-beta, data-driven clinical bet increasingly looks like a strategic M&amp;A optionality trade, with a potential floor under the stock—at least in the near term.<img src="https://news.stocktwits-cdn.com/Abivax_since_IPO_png_b0a5af2a71.webp" alt="Abivax since IPO.png">Source: Koyfin<h2 class="st-heading-2">From Clinical Breakout to Strategic Asset</h2>For all the hype around the name, Abivax is still&nbsp;more or less a one-trick pony. Its lone pipeline asset and lead candidate, Obefazimod, is an immunomodulator that is being evaluated for multiple indications. The indication that is&nbsp;most developed is moderately to severely active ulcerative colitis (UC).&nbsp;Obefazimod acts by enhancing the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Inflammatory Bowel Disease (IBD), a broader term used to refer to chronic conditions such as UC and Crohn’s disease, is an autoimmune response. The immune system mistakenly attacks the gut, causing inflammation and damage to the digestive tract, leading to symptoms such as diarrhea, abdominal pain, weight loss and fatigue.&nbsp;UC affects the large intestine and rectum, causing ulcers on the inner lining, and Crohn’s disease can affect any part of the gastrointestinal tract and inflames the entire bowel wall.&nbsp;Is the condition such a big opportunity? By Abivax’s own account, it seems so. In a corporate presentation, the company said, citing Evaluate data, that IBD prevalence was 3.6 million in the G7 nations in 2024, with roughly 64% in the U.S. The prevalence is expected to grow at a modest 4% pace over the next six years. Worldwide IBD drug sales in 2024 are estimated at $23.7 billion, with 70% from the U.S.<h4 class="st-heading-4" style="text-align:center;">Worldwide IBD Sales&nbsp;</h4><figure class="image"><img style="aspect-ratio:661/535;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_1_48_03_AM_png_2f93920926.webp" alt="Screenshot 2025-12-24 at 1.48.03 AM.png" width="661" height="535"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Source: AbivaxThe current treatment options include:-Interleukin-23 selective inhibitors (block the action of pro-inflammatory cytokine protein interleukin-23)-Sphingosine 1-phosphate (S1P) modulators such as ozanimod and etrasimod (target proteins linked to inflammation on immune cells and stop them from leaving the lymph nodes)-Janus Kinase (JAK) inhibitors (stop several types of pro-inflammatory cytokines from forming)Abivax projects Obefazimod as a differentiated treatment option compared to existing therapies, by enhancing the expression of microRNA-124, a natural regulator of the inflammatory response. The mode of administration is also convenient: an oral once-daily pill with a favorable long-term safety profile.<h2 class="st-heading-2">Wall Street Analysts’ Optimism Abounds</h2>Following topline data from two Phase 3 studies showing the candidate met the primary and secondary endpoints, Abivax stock received love from several Wall Street firms, with Morgan Stanley upgrading the stock to an ‘Overweight,’ according to the Fly.&nbsp;The pooled placebo-adjusted clinical remission for the 50mg dose of 16.4% came in above the roughly 15% bar that Morgan Stanley analysts estimated based on their conversations with investors and experts. The analyst also expected improved odds of success across UC and Crohn's.&nbsp; Guggenheim analysts estimated Obefazimod’s value at $7 billion to $10 billion.Piper Sandler analysts said following the Phase 3 data, they have layered in revenue in early-line UC. This doubles its U.S. UC estimate to 2.66 billion euros ($3.14 billion) in 2035, suggesting there could be significant upside to the stock ahead of key data events.Abivax presented the results of the two late-stage studies at the United European Gastroenterology (UEG) Meeting in Berlin in early October. Citizen JMP analysts, who upped their price target ahead of the event, said the data reinforce Obefazimod’s efficacy and increase conviction in its multi-billion-dollar sales potential. Guggenheim named Abivax as a “Best Idea” and upped its price target to $150.&nbsp;Last month, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $176 price target. The firm based its optimistic assessment on its belief that the company’s odds of success in Crohn’s disease may be higher than those of UC. Crohn’s readout would be a better catalyst in 2026, it added.According to Koyfin, the average analyst price target for Abivax stock is $138.35, implying a 22% downside from current levels. Of the five analysts covering the stock, four have either a ‘Buy’ or a ‘Strong Buy’ rating, and one remains on the sidelines.<h2 class="st-heading-2">Retail Jump Onto Bullish Bandwagon</h2>The Abivax stock stream on Stocktwits has attracted a large following, with the watcher count jumping over 5,500% in the past year. The 30-day message volume is up 2,100%.&nbsp;Retail sentiment toward the stock was ‘extremely bullish’ as of early Wednesday, and it has mainly remained upbeat throughout the year. A bullish&nbsp;<a href="https://stocktwits.com/jeremy0916/message/639921688">watcher</a> has already set his sights on the $230 level for a stock that ended Tuesday’s session at $138.35.<figure class="image"><img style="aspect-ratio:724/433;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_3_01_43_AM_png_3c8d4a0547.webp" alt="Screenshot 2025-12-24 at 3.01.43 AM.png" width="724" height="433"></figure><h2 class="st-heading-2">Key Catalysts Investors Are Watching</h2>Fresh off its addition to the Nasdaq Biotechnology Index, Abivax is entering a catalyst-rich phase. The topline results from an ongoing 44-week maintenance trial, dubbed ABTECT-107, are expected to be read out in the second quarter of 2026. The company also plans to release topline data from the Phase 2 Crohn’s Disease study in the second half of next year.<h2 class="st-heading-2">Why Lilly Might Be Interested</h2>Obefazumod could be a better fit in Lilly’s immunology franchise, which includes Omvoh, an IL-23 inhibitor, used as a second-line treatment for adults with moderately to severely active UC and Crohn’s disease. It is administered as an IV infusion. Lilly also acquired Morphic Pharma, thereby adding an oral integrin blocker for UC.Abivax’s current market valuation is roughly $11 billion. The company’s cash position as of Sept. 2025 is 589.7 million euros, and the company said it has a cash runway into the fourth quarter of 2027.&nbsp;Whether that Lilly deal materializes or not, Abivax enters 2026 with elevated expectations, higher stakes, and far more eyes on the name than ever before.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-s-worst-year-in-four-decades-may-end-thanks-to-a-weight-loss-pill/cLepFr2REuw">Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill</a>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Equity

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.


ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Shares of PepGen (PEPG) more than doubled on Thursday morning after multiple analysts raised their price targets on the stock following the release of positive clinical data from an early-stage study in patients with myotonic dystrophy type 1.Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.Myotonic dystrophy type 1 (DM1) is a progressive disorder that primarily affects skeletal, cardiac, and smooth muscle. It is estimated to affect about 40,000 patients in the U.S.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-highest-mean-splicing-correction-reported-dm1">announced</a> on Wednesday that a 53.7% mean splicing correction was observed in DM1 patients following a single 15 mg/kg dose of its PGN-EDODM1, which is higher than any previously reported splicing correction in DM1 patients. All patients who received the dose in the trial showed an improvement in splicing correction, the company noted.“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies,” said Paul Streck, Executive Vice President of Research and Development at PepGen.The company previously reported mean splicing correction of 12.3% and 29.1%, respectively, with 5mg/kg and 10mg/kg doses of PGN-EDODM1.The investigational candidate was well-tolerated at a dose of 15 mg/kg, and no serious treatment-related adverse events were identified, the company stated. However, one patient had to receive oral antihistamines for treatment-related adverse events, it said.PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PEPG">PEPG stock </a>rose from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;PEPG stock is up 51% this year but down approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Shares of genetics research company 23andMe Holding Co, which recently filed for bankruptcy, notched its best session ever on Thursday after obtaining a legal nod to start an asset sale.Late on Wednesday, 23andMe said it had secured a U.S. bankruptcy court approval for its initial Chapter 11 motions, including wage payments, vendor compensation, and a $35-million debtor-in-possession financing agreement with JMB Capital Partners.&nbsp;The court also authorized a sale process for most of its assets, requiring buyers to adhere to 23andMe's consumer privacy policies.&nbsp;The company, working with Moelis, will solicit bids over 45 days. A second hearing on further relief, including final approval of the financing facility, is set for April 22.The news sent 23andMe's stock soaring more than 45% on Thursday, although it slid in after-hours trading.On Stocktwits, message volume about 23andMe has surged by over 26,000%, while its following has grown by 4% since the company filed for bankruptcy during the weekend.Sentiment on the platform shifted from 'bearish' to 'extremely bullish' in a day.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/ME_sentiment_and_message_volume_as_of_March_27_png_50af800a78.webp" alt="ME sentiment and message volume as of March 27.png" width="1318" height="302"><figcaption>ME sentiment and message volume as of March 27. | source: Stocktwits</figcaption></figure>Retail investors speculated on potential buyouts, including one from co-founder Anne Wojcicki, who stepped down as CEO after the bankruptcy filing to pursue a takeover as "an independent bidder."One user estimated the company's genetic data alone could be worth over $1 billion, suggesting a buyout in the "$3-$5 range”&nbsp;per share.They also argued that even at a lowball valuation of $10 per user, the company could still be worth $100 million after debt, making it an attractive acquisition target.<stembedurl>https://stocktwits.com/SWIMHOLE/message/609440102</stembedurl>Another saw a Wojcicki buyout as unlikely and speculated that Big Pharma, international buyers, or even Chinese biotech firm BGI could become potential acquirers.<stembedurl>https://stocktwits.com/Jack_du/message/609505055</stembedurl>Retail investors also cited a media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/british-investor-backs-rescue-of-failing-genetics-firm-23andme-swl58rsqs">report</a> about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort."We believe this business is not only salvageable but could be worth over a billion dollars if the right changes are made," he reportedly said.23andMe, founded in 2006 by Wojcicki, Linda Avey, and Paul Cusenza, quickly became one of the hottest biotech startups with its DNA testing services that let users explore their ancestry and genetic traits through simple "spit kits" mailed to their homes.The company went public via a blank-check merger in 2021, at the height of the COVID-19 pandemic, reaching a peak market capitalization of $6 billion.&nbsp;However, by 2024, its valuation had plummeted to just $120 million as it struggled to churn a profit despite amassing a customer base of 15 million.Following its bankruptcy filing, 23andMe's login portal crashed Monday evening as users rushed to delete their genetic data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of 23andMe headquarters in Sunnyvale, California, United States on March 25, 2025. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology